Alnylam Pharmaceuticals Inc. (ALNY): Price and Financial Metrics


Alnylam Pharmaceuticals Inc. (ALNY): $231.59

2.57 (+1.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALNY POWR Grades

  • ALNY scores best on the Quality dimension, with a Quality rank ahead of 68.02% of US stocks.
  • ALNY's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • ALNY ranks lowest in Stability; there it ranks in the 28th percentile.

ALNY Stock Summary

  • ALNYLAM PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 1.39% of US listed stocks.
  • With a price/sales ratio of 29.32, ALNYLAM PHARMACEUTICALS INC has a higher such ratio than 95.2% of stocks in our set.
  • ALNY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.18% of US stocks.
  • Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are CYTK, ARGX, INSM, DCTH, and MIRM.
  • Visit ALNY's SEC page to see the company's official filings. To visit the company's web site, go to www.alnylam.com.

ALNY Valuation Summary

  • ALNY's price/sales ratio is 29.4; this is 1334.15% higher than that of the median Healthcare stock.
  • Over the past 227 months, ALNY's price/sales ratio has gone down 406.1.

Below are key valuation metrics over time for ALNY.

Stock Date P/S P/B P/E EV/EBIT
ALNY 2023-01-20 29.4 -417.7 -23.9 -28.0
ALNY 2023-01-19 29.3 -415.7 -23.8 -27.9
ALNY 2023-01-18 29.7 -421.6 -24.1 -28.3
ALNY 2023-01-17 29.9 -425.1 -24.3 -28.5
ALNY 2023-01-13 30.2 -428.4 -24.5 -28.7
ALNY 2023-01-12 29.4 -418.1 -23.9 -28.0

ALNY Growth Metrics

    The 4 year revenue growth rate now stands at 386.49%.
  • The 3 year revenue growth rate now stands at 919.64%.
  • Its 4 year cash and equivalents growth rate is now at 173.43%.
ALNY's revenue has moved up $869,119,000 over the prior 49 months.

The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 960.918 -559.437 -1,182.123
2022-06-30 884.245 -578.189 -980.717
2022-03-31 879.98 -577.226 -892.874
2021-12-31 844.287 -641.693 -852.824
2021-09-30 749.314 -614.696 -837.904
2021-06-30 687.534 -590.986 -886.681

ALNY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
  • ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
  • QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.

The table below shows ALNY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.220 0.833 -0.249
2021-06-30 0.204 0.833 -0.267
2021-03-31 0.171 0.832 -0.272
2020-12-31 0.159 0.842 -0.308
2020-09-30 0.141 0.832 -0.372
2020-06-30 0.130 0.853 -0.416

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $184.16 Average Broker Recommendation 1.64 (Moderate Buy)

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $231.59 52-week high $242.97
Prev. close $229.02 52-week low $117.58
Day low $228.77 Volume 551,111
Day high $234.02 Avg. volume 727,571
50-day MA $226.64 Dividend yield N/A
200-day MA $186.78 Market Cap 28.49B

Alnylam Pharmaceuticals Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. (Source:Wikipedia)


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam Pharmaceuticals In-Line Revenue & A Full Slate Of Clinical Read-Outs (ALNY)

Alnylam shares have continued to outperform since my last update, besting the XBI ETF by about 10%. Find out why I''m bullish on ALNY stock.

Seeking Alpha | January 10, 2023

Alnylam preliminary FY22 net product revenues for 4 drugs rises 35% Y/Y

Alnylam Pharmaceuticals (ALNY) said preliminary full year global net product revenues for its drugs Onpattro, Amvuttra, Givlaari and Oxlumo amounted to $894M, growing +35% Y/Y (+43% Y/Y…

Seeking Alpha | January 9, 2023

Alnylam Announces Preliminary Q4 Global Net Product Revenues

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced its preliminary fourth quarter 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.Preliminary global…

Finanz Nachrichten | January 9, 2023

Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22

Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

Yahoo | January 9, 2023

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches. Preliminary Fourth Quarter and Full Year 2022 Commercial and Financial Performance* Total TTR:

Wallstreet:Online | January 8, 2023

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -0.31%
3-mo 13.24%
6-mo 63.05%
1-year 77.98%
3-year 97.89%
5-year 72.33%
YTD -2.55%
2022 40.14%
2021 30.48%
2020 12.85%
2019 57.96%
2018 -42.61%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7391 seconds.